Oklo shares are lower in Monday trading (March 30, 2026) as the market extends a pullback that followed a wave of recent analyst target reductions. The common thread in the cuts is near-term execution risk and the funding/capex burden required to advance regulatory approvals and begin building toward first deployments.

In the last two weeks, analysts have pointed to sharply higher 2026 spending as a key reason valuation multiples are being reined in. Goldman Sachs lowered its price target to $65 from $91 while keeping a Neutral stance, citing higher operating expenses and guidance for significantly higher 2026 capex of $350 million to $450 million. UBS also reduced its price target to $60 from $95, maintaining Neutral, explicitly flagging greater short-term execution risk and higher nuclear-project capex with potential cost overruns.

Oklo remains pre-revenue, which makes changes in the expected cash burn and build timetable especially important to investors. When capex expectations move higher, the market often prices in a higher probability of future capital raises and/or a longer path to commercialization, which can weigh on shares even if long-term demand drivers (like data-center power needs) remain intact.

Investors will be focused on whether Oklo can hit upcoming commercialization and regulatory milestones without further cost inflation, and whether additional strategic/customer announcements can offset near-term funding concerns. Any updates that clarify project timelines, financing plans, or partner participation could quickly change sentiment given how sensitive early-stage nuclear developers are to execution signals.